Trudel, Nathalie ; Garg, Revendra ; Messier, Nadine ; Sundar, Shyam ; Qoullette, Marc ; Tremblay, Michel J. (2008) Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors Journal of Infectious Diseases, 198 (9). pp. 1292-1299. ISSN 0022-1899
Full text not available from this repository.
Official URL: http://jid.oxfordjournals.org/content/198/9/1292.a...
Related URL: http://dx.doi.org/10.1086/592280
Abstract
Visceral leishmaniasis is now recognized as an opportunistic disease in individuals infected with human immunodeficiency virus type 1 (HIV-1). Although the usefulness of HIV-1 protease inhibitors (PIs) in antiretroviral regimens is well documented, little is known about their potential impact in the setting of Leishmania/HIV-1 coinfections. We now report that, although selected PIs do not inhibit the growth of Leishmania infantum promastigotes alone in culture, these drugs significantly inhibit the intracellular survival of parasites in phorbol myristate acetate-differentiated THP-1 macrophages and human primary monocyte-derived macrophages (MDMs). Furthermore, a field isolate of Leishmania donovani resistant to sodium stibogluconate (SbV), one of the drugs most commonly used to treat leishmaniasis, is equally susceptible to the tested PIs compared with a sensitive strain, thus suggesting that resistance to SbV does not result in cross-resistance to PIs. Importantly, the efficacy of PIs to reduce the intracellular growth of Leishmania parasites is also observed inMDMscoinfected with HIV-1.
Item Type: | Article |
---|---|
Source: | Copyright of this article belongs to University of Chicago Press. |
ID Code: | 71303 |
Deposited On: | 25 Nov 2011 07:29 |
Last Modified: | 25 Nov 2011 07:29 |
Repository Staff Only: item control page